{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:13Z","timestamp":1790312413170,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Background<\/jats:title>\n Telitacicept is a TACI-Fc fusion protein that targets both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Evidence in adults with systemic lupus erythematosus (SLE) includes placebo-controlled randomized trials, other comparative studies, and single-arm cohorts.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To assess the efficacy and safety of telitacicept in adults with SLE and to synthesize placebo-controlled randomized trials, other comparative studies, and single-arm treatment cohorts separately by study design.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We searched electronic databases, screened references, and conducted hand searches, and cross-checked international trial registries. Eligible studies enrolled adults with SLE, including lupus nephritis (LN) subgroups. Comparative binary outcomes were pooled as risk ratios (RRs), continuous outcomes as mean differences (MDs), and single-arm outcomes as logit-transformed proportions. Random-effects models were used, and evidence certainty was assessed using GRADE.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Thirty-nine reports, all from China, were included, and 22 contributed to quantitative synthesis. In two placebo-controlled randomized trials, telitacicept 160\u2005mg plus standard therapy increased SLE Responder Index-4 (SRI-4) response at 48\u201352 weeks (RR\u2009=\u20092.04, 95% CI 1.66\u20132.50; I2\u2009=\u20090.0%) and slightly increased any adverse events (RR\u2009=\u20091.09, 95% CI 1.02\u20131.17). No clear difference was observed for serious adverse events (RR\u2009=\u20090.68, 95% CI 0.35\u20131.30). Observational comparative findings in adult LN and single-arm cohort proportions were assessed separately. GRADE rated SRI-4 response and any adverse event as moderate certainty, serious adverse events as low certainty, and all other outcomes as very low certainty.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In the Chinese populations studied, telitacicept 160\u2005mg plus standard therapy probably improves SRI-4 response at 48\u201352 weeks in adults with active SLE and may slightly increase any adverse events. Evidence for other outcomes is uncertain and does not establish comparative efficacy or long-term safety.<\/jats:p>\n <\/jats:sec>\n \n Systematic Review Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261464193<\/jats:ext-link>\n , PROSPERO CRD420261464193.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1959776","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:28:04Z","timestamp":1790310484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of telitacicept in adults with systemic lupus erythematosus: a systematic review and stratified meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zihua","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhai","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1046687","DOI":"10.3389\/fphar.2022.1046687","article-title":"Targeting type I interferons in systemic lupus erythematous","volume":"13","author":"Bruera","year":"2023","journal-title":"Front Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e000469","DOI":"10.1136\/lupus-2020-000469","article-title":"Living with systemic lupus erythematosus in 2020: a European patient survey","volume":"8","author":"Cornet","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11219","DOI":"10.1038\/s41598-022-15549-0","article-title":"Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus","volume":"12","author":"Ortiz-Aljaro","year":"2022","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"107904","DOI":"10.1016\/j.intimp.2021.107904","article-title":"The PI3K\u03b4 inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and sj\u04e7gren\u2019s syndrome","volume":"98","author":"Scuron","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/path.6353","article-title":"APRIL\/BAFF upregulation is associated with clonal B-cell expansion in hunner-type interstitial cystitis","volume":"264","author":"Horie","year":"2024","journal-title":"J Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"","journal-title":"Br Med J"},{"key":"B10","article-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"Wells","year":"2000","journal-title":"Ottawa Hospital Research Institute"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jclinepi.2007.03.006","article-title":"The use of missingness screens in clinical epidemiologic research has implications for regression modeling","volume":"60","author":"Van Ness","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"B13","first-page":"37","article-title":"Efficacy of telitacicept combined with conventional therapy in the treatment of severe systemic lupus erythematosus","volume":"42","author":"Yang","year":"2026","journal-title":"Chin Community Doctors"},{"key":"B14","first-page":"92","article-title":"Efficacy and safety of telitacicept in the treatment of moderate-to-severe active systemic lupus erythematosus","volume":"24","author":"Jia","year":"2026","journal-title":"Contemp Med Symp"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1806712","DOI":"10.3389\/fimmu.2026.1806712","article-title":"B-cell subset changes and clinical predictors of telitacicept response in SLE patients with antiphospholipid antibody positivity: a prospective observational cohort study","volume":"17","author":"Sun","year":"2026","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1826829","DOI":"10.3389\/fimmu.2026.1826829","article-title":"Efficacy and safety of telitacicept as an add-on therapy for relapsing lupus nephritis: a retrospective cohort study","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-025-03724-3","article-title":"A BAFF\/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a long-term, observational, real-world study","volume":"28","author":"Wei","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-026-05307-w","article-title":"Efficacy of telitacicept on renal outcomes in patients with biopsy-proven lupus nephritis: a 12-month follow-up pilot study","author":"Zhang","year":"2026","journal-title":"Int Urol Nephrol"},{"key":"B19","first-page":"87","article-title":"Clinical observation of telitacicept combined with a standard regimen in patients with systemic lupus erythematosus","volume":"34","author":"Zhang","year":"2025","journal-title":"China Pharm"},{"key":"B20","first-page":"1367","article-title":"Clinical study of telitacicept combined with cyclophosphamide in patients with systemic lupus erythematosus","volume":"41","author":"Shen","year":"2025","journal-title":"Chin J Clin Pharmacol"},{"key":"B21","first-page":"30","article-title":"Clinical observation of telitacicept combined with prednisone for systemic lupus erythematosus and its effects on liver function","volume":"9","author":"Li","year":"2025","journal-title":"Mod Med Health Res Electron J"},{"key":"B22","author":"Ye","year":"2025"},{"key":"B23","first-page":"24","article-title":"Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus","volume":"18","author":"Zeng","year":"2025","journal-title":"Chin J Clin Ration Drug Use"},{"key":"B24","author":"Pan","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1608085","DOI":"10.3389\/fmed.2025.1608085","article-title":"BAFF\/APRIL expression-guided telitacicept therapy demonstrates superior efficacy in systemic lupus erythematosus patients: a real-world comparative study","volume":"12","author":"Huang","year":"2025","journal-title":"Front Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e001296","DOI":"10.1136\/lupus-2024-001296","article-title":"Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study","volume":"12","author":"Chen","year":"2025","journal-title":"Lupus Sci Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10067-024-07266-y","article-title":"Effectiveness and safety of belimumab and telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study","volume":"44","author":"Jin","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s10067-025-07348-5","article-title":"Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study","volume":"44","author":"Fang","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1613790","DOI":"10.3389\/fphar.2025.1613790","article-title":"Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"114596","DOI":"10.1016\/j.intimp.2025.114596","article-title":"Efficacy and safety of telitacicept in patients with class III\u2013V lupus nephritis: a real-world retrospective cohort study","volume":"154","author":"Chen","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10238-025-01640-z","article-title":"Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study","volume":"25","author":"Feng","year":"2025","journal-title":"Clin Exp Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1610136","DOI":"10.3389\/fimmu.2025.1610136","article-title":"Impact of telitacicept on gonadal function in adult female patients with systemic lupus erythematosus: a prospective cohort study","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13075-025-03584-x","article-title":"Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus","volume":"27","author":"Chen","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/ndt\/gfaf049","article-title":"Real world data on dual BLyS\/APRIL inhibition with telitacicept for lupus nephritis","volume":"40","author":"Jin","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1645826","DOI":"10.3389\/fimmu.2025.1645826","article-title":"Research paper efficacy and safety of telitacicept combined with standard therapy for lupus nephritis: a single-center real-world study","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/09612033241311330","article-title":"The effectiveness of telitacicept in patients with systemic lupus erythematosus: a retrospective, real-world study","volume":"34","author":"Hu","year":"2025","journal-title":"Lupus"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.12677\/acm.2024.1451600","article-title":"The efficacy of telitacicept in the treatment of patients with systemic lupus erythematosus combined with antiphospholipid syndrome","volume":"14","author":"Gai","year":"2024","journal-title":"Advances in Clinical Medicine"},{"key":"B39","author":"Xu","year":"2024"},{"key":"B40","first-page":"2871","article-title":"Clinical study of telitacicept combined with hydroxychloroquine sulfate in the treatment of systemic lupus erythematosus","volume":"39","author":"Li","year":"2024","journal-title":"Drugs Clin"},{"key":"B41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3969\/j.issn.1002-5944.2024.12.048","article-title":"Effects of standardized telitacicept treatment in patients with moderate-to-severe systemic lupus erythematosus","author":"Niu","year":"2024","journal-title":"China Stand"},{"key":"B42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1002\/mco2.515","article-title":"B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept","volume":"5","author":"Ji","year":"2024","journal-title":"MedComm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study","volume":"28","author":"Huang","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1423035","DOI":"10.3389\/fimmu.2024.1423035","article-title":"Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: a real-life, single-center observational study","volume":"15","author":"Fan","year":"2024","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s10067-024-06992-7","article-title":"Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement","volume":"43","author":"Cheng","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B47","first-page":"97","article-title":"Clinical observation of telitacicept combined with a standard regimen for type III-V active lupus nephritis","volume":"32","author":"Lin","year":"2023","journal-title":"China Pharm"},{"key":"B48","author":"Qi","year":"2023"},{"key":"B49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e001074","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B51","first-page":"1637","article-title":"Efficacy and safety of telitacicept in the treatment of moderate-to-severe active systemic lupus erythematosus","volume":"55","author":"Jiang","year":"2020","journal-title":"Jiangxi Med J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e001980","DOI":"10.1136\/lupus-2026-001980","article-title":"Impact of belimumab on the utility of serological markers for assessing systemic lupus erythematosus activity","volume":"13","author":"Moreno-Torres","year":"2026","journal-title":"Lupus Sci Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1737281","DOI":"10.3389\/fimmu.2026.1737281","article-title":"Complement and autoantibody levels under anifrolumab therapy in SLE: implications for clinical practice","volume":"17","author":"Rademacher","year":"2026","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1177\/09612033221107534","article-title":"Differential impact of disease activity and damage on health-related quality of life in patients with systemic lupus erythematosus","volume":"31","author":"Riaz","year":"2022","journal-title":"Lupus"},{"key":"B55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00393-022-01250-0","article-title":"Lupusnephritis","volume":"82","author":"Mucke","year":"2023","journal-title":"Z Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/picr.picr_217_21","article-title":"Observational designs for real-world evidence studies","volume":"13","author":"Taur","year":"2022","journal-title":"Perspect Clin Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1959776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:28:06Z","timestamp":1790310486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1959776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":56,"alternative-id":["10.3389\/fmed.2026.1959776"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1959776","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1959776"}}